期刊
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
卷 5, 期 10, 页码 1313-1322出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/17425250903273160
关键词
adverse events; HAART; HIV; pharmacodynamics; pharmacokinetics; protease inhibitor; saquinavir; toxicity; viral efficacy
资金
- Abbott Laboratories
- Bristol-Myers Squibb
- Merck
- Roche
- Boehringer Ingelheim
- Pfizer
- Tibotec
Background: The treatment of HIV infection underwent a major change in 1995 when saquinavir was the first protease inhibitor introduced into the market. This drug made the use of combination therapy in the treatment of HIV possible and increased the success rate of treatment. Objective: This article will review recent literature on saquinavir to define its current role in HIV treatment, among the newer antiretroviral drugs. Methods: Scientific literature and conference presentations were evaluated for relevant information pertaining to saquinavir. Results/conclusions: Although underused, saquinavir has good efficacy and tolerability when compared to other protease inhibitors. The film-coated tablet formulation improved pill burden. Saquinavir still has potential in the treatment of adults, children and pregnant women.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据